Citius Oncology, INC 10-Q quarterly reports

Citius Oncology, Inc. reported its first revenue from LYMPHIR sales in Q1 2026, significantly narrowing its net loss, but faces ongoing going concern doubts and a need for further capital.

Citius Oncology reports increased losses and a going concern warning despite FDA approval for LYMPHIR and recent capital raise, as it prepares for commercial launch.

Citius Oncology's Q2 2025 report reveals a net loss of $14.4 million and raises concerns about its ability to continue as a going concern due to reliance on funding from Citius Pharma and the need for additional capital.

Citius Oncology's Q1 2025 report highlights ongoing efforts to commercialize LYMPHIR, with increased operating expenses and reliance on funding from Citius Pharma.

Citius Oncology, formerly TenX Keane Acquisition, reported a net income of $742,291 for the first six months of 2024, primarily driven by interest income from its trust account, while progressing towards a business combination with Citius Pharmaceuticals.

TenX Keane Acquisition reported a net income of $489,829 for the first quarter of 2024, primarily driven by investment income, while actively pursuing a business combination with Citius Oncology.